Related Experiment Video

Updated: May 9, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

The temporary drop of serum octreotide concentration deteriorated ventricular tachycardia in an acromegalic patient

Tetsuhiro Kitamura1, Michio Otsuki, Masaya Yamaoka

  • 1Department of Metabolic Medicine, Osaka University Graduate school of Medicine, Suita 565-0871, Japan.

Endocrine Journal
|July 17, 2013
PubMed

Insights

Acromegaly patients with dilated hypertrophic cardiomyopathy and ventricular tachycardia may experience VT control issues when switching octreotide formulations. Maintaining serum octreotide levels during transitions is crucial for managing severe arrhythmias.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Acromegaly commonly causes left ventricular hypertrophy (LVH), leading to ventricular dysfunction and potentially ventricular arrhythmias.
  • Hypertrophic cardiomyopathy (HCM) can progress to a dilated phase, increasing the risk of ventricular tachycardia (VT).
  • The combination of dilated HCM and VT in acromegaly patients is rarely reported.

Observation:

  • A 56-year-old male with acromegaly presented with dilated HCM and sustained VT.
  • Subcutaneous octreotide injections initially improved VT frequency and severity.
  • Switching to octreotide long-acting release (LAR) led to VT deterioration, linked to a temporary drop in serum octreotide concentration.

Findings:

  • This case highlights the first reported instance where changes in serum octreotide concentration influenced VT control in a patient with dilated HCM secondary to acromegaly.
  • The transition from subcutaneous to octreotide LAR injections caused a temporary decrease in serum octreotide levels, correlating with worsened VT.
  • Consistent serum octreotide levels appear critical for managing severe arrhythmias in this patient population.

Implications:

  • Subcutaneous octreotide injections for two weeks may be necessary to maintain therapeutic serum octreotide concentrations during the transition to octreotide LAR.
  • This finding provides crucial information for managing acromegalic patients with severe cardiac complications like dilated HCM and VT.
  • Optimizing octreotide administration strategies can improve arrhythmia control and patient outcomes in acromegaly.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Increased pulse rate01:17

Increased pulse rate

Tachycardia is a condition marked by an abnormally fast or irregular heart rate, surpassing the typical resting rate. In adults, tachycardia is characterized by a pulse rate ranging from 100 to 180 beats per minute. The increased heart rate can result in inadequate blood flow to various body parts, ultimately diminishing the oxygen supply to organs and tissues.
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...